ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Brief Correspondence

FH Groenendijk, J. de Jong, EE Fransen van de Putte, M Michaut, A Schlicker, D Peters, A Velds, MS van der Heijden

Research output: Contribution to journalArticleScientificpeer-review

116 Citations (Scopus)
Original languageEnglish
Pages (from-to)384-388
Number of pages5
JournalEuropean Urology
Volume69
Issue number3
DOIs
Publication statusIn preparation - 2015

Bibliographical note

wessels extern

Cite this